Health and FitnessHealth and Fitness
Tue, January 3, 2012
[ Tue, Jan 03rd 2012 ] - Market Wire
Sara Lee adquiere Tea Fort
[ Tue, Jan 03rd 2012 ] - Market Wire
Sara Lee Acquires Tea Fort

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference


Published on 2012-01-03 06:41:27 - Market Wire
  Print publication without navigation


Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference -- TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ --

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference

[ ]

TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at the 30th Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2012.  The presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time).  The session may be accessed through the Company's web site, [ www.regeneron.com ], on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through February 8, 2012. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contact Information:                             

 

Michael Aberman, M.D.                        

Peter Dworkin

Investor Relations                                   

Corporate Communications

914.847.7799                                       

914.847.7800

[ michael.aberman@regeneron.com ]       

[ peter.dworkin@regeneron.com ]

 

 

SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]